We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 3.28% | 1.575 | 1.50 | 1.65 | 1.625 | 1.575 | 1.60 | 4,556,518 | 09:01:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 891k | -11.89M | -0.0098 | -1.60 | 18.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/11/2024 08:21 | Revenues are up 3,000% so the strategy is working. :) | m_night10 | |
13/11/2024 08:18 | Fundamental question here.Is commercial traction occurring? Have polarean seen any benefit of a partnership with Philips over a year ago?Simple answer which rampers hate... NO.Ps rampers never believe in a company they only try to ramp a spike, they would be first out, and investors sucked in are left holding the baby and the losses. This won't ever spike without further commercial news. Expected late spring if the sales guys are on the road talking to institutions rather than cheap finance news websites where you pay to be an advertorial | moontheloon | |
13/11/2024 08:15 | POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. | m_night10 | |
13/11/2024 07:54 | The share price actually went down after the new investors presentation day. Incredible. And that people was the last newslow.And 1/5 of cash runway spent since any news. The last commercial news was an upgrade which is literally a free part exchange. Over 3.5 months ago a full qtr has passed. The cash runway is shortening all the time, all the rampers at present are the ones who deramped the company last year when money and cash runway was running out. Better hope for quick commercial traction when budgets re open in spring 2025. As summer 2025 is the 6 months tick down to finance. A cash call would start to be orchestrated in this six months. For newbies, this went from 200m shares in issue, to 1.2 billion shares in issues at 1p dilution. This churn is massive and still only tip of this iceberg has been churned. As 1p holders take profits anywhere over 1.3pDyor people. | moontheloon | |
13/11/2024 07:44 | https://www.britishb | moontheloon | |
13/11/2024 07:35 | See why huang got time for interviews ... lol spring time for news. | moontheloon | |
12/11/2024 19:03 | Yes well spotted m_knight | robow | |
12/11/2024 16:33 | Huang Is the man does am interview says same stuff we already know and gets a few lenmings to part with some money. We keep trying to get Duke.. they're only our supposed inventors base and former cto turned consultant to all. Huang would do well to buy some shares to put some of his own risk in the game... that might inspire people to think they're not just on a luxury gravy train at their expense. | moontheloon | |
12/11/2024 16:32 | Wow this is excellent: | m_night10 | |
12/11/2024 12:32 | *we are, as I stated. | moontheloon | |
12/11/2024 12:25 | The huang proactive what is trying to achieve? He said same stuff cvj said and we know already. 2 months in post... and doing interviews he needs to be out talking to companies to sign on dotted line for sales. Even better putting his hand in his pocket and skin in the game. Would give shareholders some hope that he might achieve sales. We ate as I have stated in closed budget period for u.s institutions so can't expect much for a while. Watch cvj explain this and the reason sales traction was slow last year. When the new budgets are out in late spring 2025 the news this share price needs desperately might emerge | moontheloon | |
12/11/2024 07:47 | Anyway bigger fish to fry elsewhere. | moontheloon | |
12/11/2024 07:46 | Thry need to re evaluate AIM it's dire for a while, but this is the company not the market traction simply stopped. | moontheloon | |
12/11/2024 07:43 | What the hell are they doing behind the scenes here? Frustrating buy. Aim is a terrible investment market. Dt | danitech1 | |
12/11/2024 07:31 | It's going very much opposite way to 2p.1p is the stronger draw as time ticks on with no commercial traction unfortunately. This will change on news. But all med tech is well out of budget in the closed area cvj has explained t lemgth that nothing happens in these periods. Better out and wait for it to return to deep weakness around 1.3p.Apologies to the rampers. Nothing to ramp here currently. Sadly | moontheloon | |
12/11/2024 07:26 | POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. | m_night10 | |
12/11/2024 07:06 | Tick another day of silence off the calendar and cash runway. Von jako liked a few things on LinkedIn yesterday, at least he's paid handsomely. The sell signal on british bulls usually affects this on low volume up and down based on their l stance. See whether I'm right to sit it out. | moontheloon | |
11/11/2024 22:58 | Signal UpdateOur system's recommendation today is to SELL. The BEARISH ENGULFING pattern finally received a confirmation because the prices crossed below the confirmation level which was at 1.5500, and our valid average selling price stands now at 1.5340. The previous BUY signal was issued on 25/10/2024, 17 days ago, when the stock price was 1.3100. Since then POLX.L has risen by +17.10%.Market OutlookWe may be at a market top or at the start of a correction. The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions. Today's candlestick has a black body and its close is below the confirmation level. The bearish pattern that was previously identified is finally confirmed and a | moontheloon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions